# Cambridge Cognition wins contract for a pivotal schizophrenia clinical trial

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-wins-contract-for-a-pivotal-schizophrenia-clinical-trial/4121029731
- Published: 2021-10-26T07:10:36+01:00
- Author: Giles

**Cambridge Cognition Holdings Plc** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
which develops and markets digital solutions to assess brain health, has announced
that it has secured a contract for a further sizeable schizophrenia trial with an
existing customer.  Cambridge Cognition has been selected again to provide its proprietary
gold standard digital cognitive assessments, CANTAB^(TM), and specialist study management
services.  The latest contract is worth more than £600,000 to the Company over three
years.

Patients with schizophrenia often experience cognitive impairment, with deficits
observed in memory, attention and executive function. CANTAB^(TM) cognitive assessments
can measure these distinct processes with a high degree of sensitivity and so offers
a valuable efficacy endpoint for the novel pharmaceutical being investigated.

> **Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:**
> “We are delighted with the enduring partnership we have formed with this client
> and the award of a further order for digital technology solutions from them. This
> is also great news for us as our strategy is to broaden our offering and expand
> into more therapeutic areas. Demonstrating the value of digital cognitive assessments
> in schizophrenia drug development could provide for many more similar opportunities
> in the future.”

Share on:
